Pulmonx Co. (NASDAQ:LUNG) Position Increased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in shares of Pulmonx Co. (NASDAQ:LUNG) by 0.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 315,532 shares of the company’s stock after acquiring an additional 2,363 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Pulmonx were worth $2,142,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LUNG. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Pulmonx in the 3rd quarter valued at $480,000. FMR LLC grew its holdings in shares of Pulmonx by 11.2% in the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock worth $48,686,000 after purchasing an additional 591,859 shares during the last quarter. PDT Partners LLC grew its holdings in shares of Pulmonx by 25.3% during the third quarter. PDT Partners LLC now owns 88,074 shares of the company’s stock worth $730,000 after purchasing an additional 17,784 shares during the last quarter. PFM Health Sciences LP bought a new stake in shares of Pulmonx during the third quarter valued at approximately $3,058,000. Finally, 272 Capital LP acquired a new position in Pulmonx during the 3rd quarter valued at about $25,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Insider Buying and Selling

In other news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $7.85, for a total transaction of $157,000.00. Following the completion of the sale, the director now directly owns 991,974 shares of the company’s stock, valued at $7,786,995.90. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Steven S. Williamson sold 27,689 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $7.14, for a total transaction of $197,699.46. Following the sale, the chief executive officer now owns 194,342 shares of the company’s stock, valued at approximately $1,387,601.88. The trade was a 12.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 147,986 shares of company stock worth $1,143,673 in the last quarter. Insiders own 5.70% of the company’s stock.

Pulmonx Price Performance

Pulmonx stock opened at $6.82 on Friday. Pulmonx Co. has a one year low of $5.46 and a one year high of $10.01. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The stock’s 50 day moving average is $7.17 and its 200 day moving average is $6.96. The firm has a market cap of $271.41 million, a P/E ratio of -4.74 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The company had revenue of $23.77 million for the quarter, compared to analysts’ expectations of $22.29 million. As a group, research analysts expect that Pulmonx Co. will post -1.55 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on LUNG. D. Boral Capital initiated coverage on Pulmonx in a report on Monday, March 10th. They issued a “buy” rating and a $17.00 price target for the company. Wells Fargo & Company dropped their price objective on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Citigroup initiated coverage on shares of Pulmonx in a research report on Monday, March 10th. They set a “buy” rating on the stock. Morgan Stanley began coverage on shares of Pulmonx in a research note on Monday, March 10th. They set an “equal weight” rating on the stock. Finally, Jefferies Financial Group started coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Pulmonx presently has an average rating of “Moderate Buy” and a consensus target price of $13.36.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.